BPC-157, GLP-1s and the New Peptide Gold Rush

Sponsor: Sooo.me

Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.

See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.

Link: https://sooo.me/?ref=LTUNLOCKED

----------

Guests:

Fady Hannah-Shmouni, MD FRCPC

Founder & CEO of Hormonaly.ai

LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/

Website: https://shmouni.com/

Koehl Robinson

Founder & CEO of Celia Health

LinkedIn: https://www.linkedin.com/in/koehlrobinson/

Website: https://www.celia-rx.com/

----------

What happens when demand for peptide therapies starts moving faster than the science, regulation and clinical infrastructure surrounding them?

Phil Newman sits down with Dr. Fady Hannah-Shmouni and Koehl Robinson to explore one of longevity medicine’s fastest-moving areas: peptides. From evidence-backed GLP-1 drugs to compounds such as BPC-157 with far more limited human evidence, they examine where the science is strong, where uncertainty remains and what patients should understand before entering this rapidly expanding market.

Together they explore how a cleaner peptide supply chain could work, why testing and clinical oversight matter, and how real-world data could help fill some of the evidence gaps where randomized controlled trials remain limited. They also discuss personalized prescribing, biomarker monitoring, AI and what responsible peptide medicine could look like as the industry matures.

In this episode, you'll learn:

- Why Fady describes GLP-1s as the standout peptide class, with potential effects extending beyond weight management into appetite and other reward-related behaviors.

- Why compounds such as BPC-157 still have major evidence gaps, with much of the published literature remaining preclinical rather than based on high-quality randomized human trials.

- How Koehl says Celia RX is building a US-based supply chain with multiple stages of testing, third-party analysis and batch testing to improve transparency around peptide sourcing.

- How lab, genomic and epigenetic testing could be combined with consultations and follow-up monitoring to move peptide prescribing toward a more personalized model.

- Why AI and real-world multi-omic data could help clinicians make sense of a fragmented evidence base while researchers continue building stronger clinical evidence.

The conversation also tackles the uncomfortable reality of the peptide “gray market.” As consumer demand grows, products can vary significantly in sourcing, testing and clinical oversight. Fady and Koehl discuss why transparency around evidence and risk matters, and why better infrastructure may be essential if peptide medicine is going to move further into mainstream healthcare.

If you want to understand where peptide medicine stands today – from established therapies to experimental compounds – this episode separates the growing enthusiasm from the evidence still needed to support it.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

Host:

Phil Newman: https://qrco.de/bgXpNY